Rajani Jagana

Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

7 h-index 40 pubs 115 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Rajani Jagana, Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences, investigates various aspects of critical care and patient outcomes. Her research has examined the association between tocilizumab and an increased risk of fungal infections in critically ill COVID-19 patients with acute renal failure, with publications in 2021, 2022, and 2023. Jagana has also studied the impact of iron deficiency on clinical and hemodynamic parameters in pulmonary arterial hypertension cohorts. Additional research interests include rare clinical presentations, such as pulmonary emboli with ST elevation on ECG, and managing adverse drug reactions, including hydroxychloroquine-associated catatonia and ETI-induced urticaria. She has also published on the efficiency of personal protective equipment in healthcare settings. Jagana's work has resulted in 40 publications and 115 citations, with an h-index of 7. Key collaborators include Nikhil Meena, William T. Atchley, Sarenthia M. Epps, and Barrett J. Burger, all from the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 7
  • Publications: 40
  • Citations: 115

Selected Publications

  • Successful Management of ETI-Induced-Urticaria (2025) DOI
  • A Case of Hydroxychloroquine Associated Catatonia in SLE (2025) DOI
  • Reduction of Methicillin-resistant Staphylococcus Aureus (MRSA) Acquisition in Patients With Cystic Fibrosis: Single-center Quality Improvement Project (2025) DOI
  • Idiopathic Hypereosinophilic Syndrome in a Rare Case of Quadricuspid Aortic Valve (2024) DOI
  • Tocilizumab Is Associated with Increased Risk of Fungal Infections among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study (2023) DOI
  • A Rare Case of Pulmonary Emboli Presenting With ST Elevation on ECG (2022) DOI
  • Personal Protective Equipment Efficiency in Healthcare Emergencies: A Single-Center Experience (2022) DOI
  • Tocilizumab is Associated with Increased Risk of Fungal Infections Among Critically Ill Patients with COVID-19 and Acute Renal Failure: An Observational Cohort Study. (2021) DOI
  • Tocilizumab Is Associated with Increased Risk of Fungal Infections Among Critically Ill Patients with COVID-19 (2021) DOI

Research Interests

1. Cystic Fibrosis: I have done and been doing many research projects in field of cystic fibrosis in collaboration with Cystic Fibrosis Foundation. These international and multicenter center studies have made an impact in the lives of cystic fibrosis patients by increasing their estimated life survival and decreased hospitalizations. I am principal investigator of few ongoing multicenter studies and sub-investigator of multiple studies at our center in the field of Cystic fibrosis and non CF bronchiectasis. 2. COVID-19: I am sub-investigator of multiple COVID-19 studies currently undergoing in our Institution. 3. I involve students, residents and fellows in research projects and may of these projects and case reports have been presented in national and international pulmonary and critical care conferences 4. I have authored 7 manuscripts, which have been published in peer- reviewed international medical journals. In addition, I have made over 26 posters and presentations that have been showcased at the international conferences including American Thoracic Society, American college of physicians (ACP), society of critical care medicine (SCCM) and CHEST conferences.

Grants & Funding

  • LEAPP CF: Leadership and Education Advanced Practice Provider Fellow Program in CF 2023 Cystic Fibrosis Foundation Principal Investigator
  • No FP attached Savara, Inc Principal Investigator
  • No FP attached Savara, Inc Principal Investigator
  • CFF Care Center Award 2021_2022 Cystic Fibrosis Foundation Co-Investigator
  • A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis (IRB 298318) Arcturus Therapeutics, Inc. - Pass Through: Worldwide Clinical Trials, Inc Principal Investigator
  • Cystic Fibrosis Care Centers -2020-2021 Continuation - Continuation - Continuation Cystic Fibrosis Foundation Co-Investigator

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics